FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318450241> ?p ?o ?g. }

• W4318450241 endingPage "1009" @default.
• W4318450241 startingPage "1003" @default.
• W4318450241 abstract "Objective: To examine the survival and influential factors of an integrated approach of novel agents, autologous hematopoietic stem cell (auto-HSCT) , and maintenance therapy in patients with multiple myeloma (MM) patients from a single center over the past 15 years. Methods: In our center, 300 MM patients who received an integrated strategy of new agents, auto-HSCT, and maintenance therapy over 15 years were retrospectively and prospectively analyzed. Results: The complete remission rates (CR) and ≥very good partial remission rates (VGPR) following induction therapy, transplantation, and maintenance therapy were respectively 35.3% and 55.2% , 72.4% and 80.0% , 89.2% , and 93.4% . When compared to patients receiving double-drug induction, the ≥VGPR and ORR of patients receiving triple-drug induction were improved. No difference existed in CR, ≥VGPR, and ORR between the PAD (bortezomib + liposome doxorubicin+ dexamethasone) and RAD (lenalidomide + liposome doxorubicin + dexamethasone) regimens, but the benefits speed differed. The negative rate of flow minimal residual disease following induction, transplantation, and maintenance was 18.8% (54 cases) , 41.4% (109 cases) , and 58.7% (142 cases) , respectively. The median time to progress (TTP) was 78.7 months and the median overall survival (OS) was 109 months. The median TTP for RISS-Ⅰ-Ⅲ patients were 111.8 months, 77.4 months, and 30.6 months, and the median OS was 118.8 months, 91.4 months, and 48.5 months, respectively. At various points during treatment, the TTP and OS of patients obtaining CR and MRD negative were longer than those of patients who did not obtain CR and MRD negative. TTP was noticeably shorter in high-risk cytogenetic patients compared to standard-risk patients even when CR was acquired during induction. There was no difference in TTP between patients with high-risk cytogenetics and those with standard-risk cytogenetics if MRD negative was acquired during induction. According to a multivariate analysis, the R-ISS stage was a poor predictor of TTP and OS at various treatment intervals. Therapeutic effectiveness was a newly independent prognostic factor following treatment. Conclusion: A median survival of almost 10 years is possible for MM patients who receive an integrated strategy of induction regimens followed by auto-HSCT and maintenance therapy, which significantly improves prognosis. However, this approach did not significantly benefit high-risk cytogenetic MM patients.目的： 分析含新药诱导化疗序贯自体造血干细胞移植（auto-HSCT）、维持治疗策略治疗多发性骨髓瘤（MM）患者的预后及影响因素。 方法： 对近15年接受含新药方案诱导化疗序贯auto-HSCT、维持治疗的300例MM患者进行回顾性分析。 结果： 诱导化疗、auto-HSCT、维持治疗后的完全缓解（CR）率分别为35.3%、55.2%、72.4%，≥非常好的部分缓解（VGPR）率分别为80.0%、89.2%、93.4%；PAD方案（硼替佐米+脂质体阿霉素+地塞米松）诱导化疗的≥VGPR率、总反应率（ORR）均高于VD方案（硼替佐米+地塞米松），PAD方案和RAD方案（来那度胺+脂质体阿霉素+地塞米松）相比，CR率、≥VGPR率以及ORR差异均无统计学意义；诱导化疗、auto-HSCT、维持治疗后流式细胞术微小残留病（MRD）阴性患者在CR患者中的占比分别为18.8%（54例）、41.4%（109例）、58.7%（142例）。中位随访时间48.5（7.4~171.3）个月，全部MM患者中位疾病进展时间（TTP）为78.7个月，中位总生存（OS）时间为109.0个月；R-ISS Ⅰ、Ⅱ、Ⅲ期患者的中位TTP时间分别为111.8、77.4、30.6个月，中位OS时间分别为118.8、91.4、48.5个月。在治疗的不同阶段获得CR和MRD阴性患者的TTP、OS时间均较未获得CR和MRD阴性患者明显延长。在诱导化疗阶段获得CR的伴有高危细胞遗传学患者，其TTP短于不伴高危细胞遗传学患者；诱导化疗阶段获得MRD阴性的高危细胞遗传学患者，其TTP和不伴高危细胞遗传学患者相比差异无统计学意义。多因素分析显示，R-ISS分期在不同治疗阶段都是影响TTP和OS的不良预后因素；患者在接受治疗后，治疗获得的疗效就成为新的独立不良预后因素。 结论： 含新药诱导化疗序贯auto-HSCT、维持治疗的MM整体治疗策略具有较好的远期疗效，但高危MM患者获益不明显。." @default.
• W4318450241 created "2023-01-30" @default.
• W4318450241 creator A5000336592 @default.
• W4318450241 creator A5004614009 @default.
• W4318450241 creator A5005823964 @default.
• W4318450241 creator A5012374407 @default.
• W4318450241 creator A5014987687 @default.
• W4318450241 creator A5017165240 @default.
• W4318450241 creator A5024061606 @default.
• W4318450241 creator A5028759288 @default.
• W4318450241 creator A5047149883 @default.
• W4318450241 creator A5079098564 @default.
• W4318450241 date "2022-12-14" @default.
• W4318450241 modified "2023-10-14" @default.
• W4318450241 title "[New agents-based induction chemotherapy followed by autologous stem cell transplantation and maintenance treatment strategy for multiple myeloma: a single center retrospective study of 300 cases]." @default.
• W4318450241 cites W2044436186 @default.
• W4318450241 cites W2121735943 @default.
• W4318450241 cites W2128192762 @default.
• W4318450241 cites W2345834611 @default.
• W4318450241 cites W2412440205 @default.
• W4318450241 cites W2419002452 @default.
• W4318450241 cites W2518827451 @default.
• W4318450241 cites W2613844594 @default.
• W4318450241 cites W2622796688 @default.
• W4318450241 cites W2809698015 @default.
• W4318450241 cites W2888510276 @default.
• W4318450241 cites W3013063217 @default.
• W4318450241 cites W3126977464 @default.
• W4318450241 cites W3127986730 @default.
• W4318450241 cites W3136650788 @default.
• W4318450241 cites W3209897673 @default.
• W4318450241 doi "https://doi.org/10.3760/cma.j.issn.0253-2727.2022.12.005" @default.
• W4318450241 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36709105" @default.
• W4318450241 hasPublicationYear "2022" @default.
• W4318450241 type Work @default.
• W4318450241 citedByCount "0" @default.
• W4318450241 crossrefType "journal-article" @default.
• W4318450241 hasAuthorship W4318450241A5000336592 @default.
• W4318450241 hasAuthorship W4318450241A5004614009 @default.
• W4318450241 hasAuthorship W4318450241A5005823964 @default.
• W4318450241 hasAuthorship W4318450241A5012374407 @default.
• W4318450241 hasAuthorship W4318450241A5014987687 @default.
• W4318450241 hasAuthorship W4318450241A5017165240 @default.
• W4318450241 hasAuthorship W4318450241A5024061606 @default.
• W4318450241 hasAuthorship W4318450241A5028759288 @default.
• W4318450241 hasAuthorship W4318450241A5047149883 @default.
• W4318450241 hasAuthorship W4318450241A5079098564 @default.
• W4318450241 hasConcept C126322002 @default.
• W4318450241 hasConcept C141071460 @default.
• W4318450241 hasConcept C143998085 @default.
• W4318450241 hasConcept C2776063141 @default.
• W4318450241 hasConcept C2776364478 @default.
• W4318450241 hasConcept C2776611710 @default.
• W4318450241 hasConcept C2776694085 @default.
• W4318450241 hasConcept C2777408962 @default.
• W4318450241 hasConcept C2777478702 @default.
• W4318450241 hasConcept C2778283404 @default.
• W4318450241 hasConcept C2779050716 @default.
• W4318450241 hasConcept C2780073493 @default.
• W4318450241 hasConcept C2780401358 @default.
• W4318450241 hasConcept C2911091166 @default.
• W4318450241 hasConcept C71924100 @default.
• W4318450241 hasConceptScore W4318450241C126322002 @default.
• W4318450241 hasConceptScore W4318450241C141071460 @default.
• W4318450241 hasConceptScore W4318450241C143998085 @default.
• W4318450241 hasConceptScore W4318450241C2776063141 @default.
• W4318450241 hasConceptScore W4318450241C2776364478 @default.
• W4318450241 hasConceptScore W4318450241C2776611710 @default.
• W4318450241 hasConceptScore W4318450241C2776694085 @default.
• W4318450241 hasConceptScore W4318450241C2777408962 @default.
• W4318450241 hasConceptScore W4318450241C2777478702 @default.
• W4318450241 hasConceptScore W4318450241C2778283404 @default.
• W4318450241 hasConceptScore W4318450241C2779050716 @default.
• W4318450241 hasConceptScore W4318450241C2780073493 @default.
• W4318450241 hasConceptScore W4318450241C2780401358 @default.
• W4318450241 hasConceptScore W4318450241C2911091166 @default.
• W4318450241 hasConceptScore W4318450241C71924100 @default.
• W4318450241 hasIssue "12" @default.
• W4318450241 hasLocation W43184502411 @default.
• W4318450241 hasOpenAccess W4318450241 @default.
• W4318450241 hasPrimaryLocation W43184502411 @default.
• W4318450241 hasRelatedWork W2033089666 @default.
• W4318450241 hasRelatedWork W2067463209 @default.
• W4318450241 hasRelatedWork W2203003885 @default.
• W4318450241 hasRelatedWork W2470933183 @default.
• W4318450241 hasRelatedWork W2496924072 @default.
• W4318450241 hasRelatedWork W2604776612 @default.
• W4318450241 hasRelatedWork W3025827814 @default.
• W4318450241 hasRelatedWork W4206235322 @default.
• W4318450241 hasRelatedWork W4284886781 @default.
• W4318450241 hasRelatedWork W4362657418 @default.
• W4318450241 hasVolume "43" @default.
• W4318450241 isParatext "false" @default.
• W4318450241 isRetracted "false" @default.
• W4318450241 workType "article" @default.